Japan Tissue Engineering Co., Ltd. (TYO:7774)
Japan · Delayed Price · Currency is JPY 590.00
-21.00 (-3.44%)
Jun 24, 2026, 11:29 AM JST
Japan Tissue Engineering Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,183 | 1,723 | 1,648 | 1,613 | 1,712 |
Other Revenue | 0 | 732 | 866 | 419 | 391 |
| 2,183 | 2,455 | 2,514 | 2,032 | 2,103 | |
Revenue Growth (YoY) | -11.09% | -2.35% | 23.72% | -3.38% | -6.82% |
Cost of Revenue | 915.39 | 944 | 823 | 896 | 848 |
Gross Profit | 1,267 | 1,511 | 1,691 | 1,136 | 1,255 |
Selling, General & Admin | 1,339 | 1,147 | 1,057 | 1,221 | 1,123 |
Research & Development | 497.32 | 506 | 407 | 573 | 561 |
Other Operating Expenses | 42.19 | 55 | 59 | 49 | 52 |
Operating Expenses | 1,919 | 1,749 | 1,546 | 1,864 | 1,753 |
Operating Income | -652.06 | -238 | 145 | -728 | -498 |
Interest & Investment Income | 9.78 | 2 | - | 1 | 2 |
Currency Exchange Gain (Loss) | -0.46 | - | - | -1 | - |
Other Non Operating Income (Expenses) | 105.29 | 1 | 1 | 2 | 3 |
EBT Excluding Unusual Items | -537.44 | -235 | 146 | -726 | -493 |
Gain (Loss) on Sale of Investments | -150 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -1 |
Asset Writedown | -43.33 | -10 | -130 | - | - |
Other Unusual Items | - | 10 | 130 | - | - |
Pretax Income | -730.78 | -235 | 146 | -726 | -494 |
Income Tax Expense | 3.98 | 20 | 3 | 3 | 3 |
Net Income | -734.75 | -255 | 143 | -729 | -497 |
Net Income to Common | -734.75 | -255 | 143 | -729 | -497 |
Shares Outstanding (Basic) | 41 | 41 | 41 | 41 | 41 |
Shares Outstanding (Diluted) | 41 | 41 | 41 | 41 | 41 |
EPS (Basic) | -18.09 | -6.28 | 3.52 | -17.95 | -12.24 |
EPS (Diluted) | -18.09 | -6.28 | 3.52 | -17.95 | -12.24 |
Free Cash Flow | -562.67 | -224 | 78 | -771 | -328 |
Free Cash Flow Per Share | -13.86 | -5.52 | 1.92 | -18.98 | -8.08 |
Gross Margin | 58.06% | 61.55% | 67.26% | 55.91% | 59.68% |
Operating Margin | -29.87% | -9.70% | 5.77% | -35.83% | -23.68% |
Profit Margin | -33.66% | -10.39% | 5.69% | -35.88% | -23.63% |
Free Cash Flow Margin | -25.78% | -9.12% | 3.10% | -37.94% | -15.60% |
EBITDA | -494.68 | -80 | 279 | -597 | -374 |
EBITDA Margin | -22.66% | -3.26% | 11.10% | -29.38% | -17.78% |
D&A For EBITDA | 157.38 | 158 | 134 | 131 | 124 |
EBIT | -652.06 | -238 | 145 | -728 | -498 |
EBIT Margin | -29.87% | -9.69% | 5.77% | -35.83% | -23.68% |
Effective Tax Rate | - | - | 2.05% | - | - |
Revenue as Reported | 2,183 | - | - | - | - |